CYP2C19 and acute coronary syndrome: Moreover, a commercial company has developed a rapid point-of-care pharmacogenetic test for CYP2C19 (granted FDA 510k clearance in March 2023), which can be performed at the patients’ bedside directly from a buccal swab and provide results in as little as 1–2 hours.48 In the RAPID GENE trial,49 patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome or stable angina were randomly assigned to rapid point-of-care pharmacogenetic testing for CYP2C19*2 or the standard of care.